ClinicalTrials.gg
CompletedNCT06827431Updated Oct 30, 2026

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

A Phase 3 interventional study of Ammoxetine and Ammoxetine in Major Depressive Disorder (MDD), sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Now CompletedFirst site in China+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
786
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Depressive Disorder, Major with a site in China — 74 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Enrollment
13th of 173
786 · median 120
Started
2025
with 22 others
Phase 3
17 of 206
4 open now
Registered
155th of 206
by date

Among the 206 studies in Depressive Disorder, Major with a site in China, this one is the 13th largest by enrollment of the 173 interventional ones that give a count, is one of 23 that started in 2025, is one of 17 in phase 3, and was the 155th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

74 of the 206 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Read the detailed description

In this study, a randomized, double-blind, double-dummy, placebo-controlled and Sertraline active-controlled multicenter study will be conducted to evaluate the efficacy and safety of different doses of Ammoxetine hydrochloride enteric coated tablets in the treatment of depression.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subjects aged 18 and 65 years (inclusive), no gender limitation;
  • 2. Subject has recurrent Major Depressive Disorder (MDD) as the primary diagnosis according to (DSM-5, 5th Edition), single episode or recurrent episodes (classification code 296.2/296.3).The duration of the current depressive episode should be ≥3 months for first-episode patients and ≥1 month for relapsing patients;
  • 3. Subjects with a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 26 at screening and baseline. Subjects with Clinical Global Impression Scale Disease Severity CGI-S severity score ≥ 4 at screening and baseline. Score of first item (depressed mood) of the HAMD-17 scale ≥2 at the screening and baseline.
  • Be able to read and understand the study procedures and trial requirements, agree to abide by the restrictions of the trial and return to the site on time for evaluation, and sign the form prior to the trial.

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects with ≥ 25% reduction in MADRS score in the baseline period compared to the screening period;
  • 2. There is a risk of suicide or risk of self-injury and harm to others. Those who meet any of the following:

    1. A score of ≥4 on item 10 (Suicidal Ideation) of the MADRS scale;
    2. Subjects who in the judgment of the investigator, are at significant risk for suicide (e.g., participant answered "yes" to question 4 (active suicidal ideation with intent to act but no specific plan) or question 5 (active suicidal ideation with a specific plan and intent) on the Screening C-SSRS and the most recent suicidal intent or suicidal plan occurred within the last six months);
    3. Attempted suicide during the current depressive episode;
  • 3. Subjects meet diagnostic criteria for other mental disorders (Schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, anxiety disorders, obsessive-compulsive and related disorders, somatic symptoms and related disorders, substance-related and addiction disorders, etc.)
  • 4. Subjects who meet any of the following diagnoses of depressive disorders:

    1. Those who have been determined by the investigator to have TRD (current or prior use of 2 or more antidepressants with different mechanisms that have not been effective with a full course (at least 8 weeks) of treatment at the full dosage (the maximum recommended amount of the instructions);
    2. Subjects with depressive disorders due to other types of mental disorders or somatic diseases (e.g., depressive disorders due to hypothyroidism);
    3. Subjects with depressive disorders due to substances/drugs;
  • 5. Subjects who stopped using the following drugs for less than 5 half-lives prior to randomization:

    1. CYP2C19 and strong inducers and strong inhibitors (e.g., fluoxetine, rifampicin, carbamazepine, etc.);
    2. Combined use of drugs that cause prolongation (e.g., levofloxacin, fluconazole, ondansetron, amiodarone, metronidazole, erythromycin, and haloperidol, etc.) or drugs that can cause QTc interval prolongation and may induce torsade de pointes ventricular tachycardia;
    3. Antipsychotics, antidepressants, or mood stabilizers;
  • 6. Subjects who have failed previous treatment with a full course (at least 8 weeks) of sertraline at the maximum recommended dose or who have a known allergy to sertraline;
  • 7. Subjects who stopped using MAOI (e.g., phenelzine, isocarbazide, antiphencyclidine, linezolid, methylene blue, etc.) for less than 2 weeks before randomization;
  • 8. Subjects on long half-life antipsychotics;
  • 9. Subjects who have received any of the following non-pharmacologic treatments within 3 months prior to screening:

    1. Electroconvulsive therapy (ECT)
    2. Systemic psychotherapy (e.g., interpersonal therapy, motivational therapy, cognitive behavioral therapy, etc.)
    3. Systemic Transcranial magnetic stimulation therapy (TMS)
    4. Systemic Vagus Nerve Stimulation (VNS)
    5. Systemic Light therapy, etc.
    6. Or those who, in the judgment of the investigator, currently require the above treatments
  • 10. Participation in any clinical trial within 3 months prior to screening;
  • 11. Those with degree II or III AV block, long QT syndrome, or QTcF >450 ms (males)/460 ms (females) on 12-lead at the time of screening, or those deemed unsuitable for enrollment by the investigator (e.g., tachyarrhythmias requiring clinical management, etc.)
  • 12. Screening subjects with or AST greater than 2 times the upper limit of laboratory normal; Severe subclinical hypothyroidism (thyroid function indices only with abnormally elevated TSH and TSH ≥ 10.0 mIU/L); Abnormalities in 2 or more of the 5 thyroid function parameters (TSH, FT3, FT4, TT3, or TT4 values less than 0.9 times the lower limit of normal or more than 1.1 times the );
  • 13. Allergic constitution (e.g. allergic to two or more drugs or to SNRIs);
  • 14. Prior history of seizures; or any other condition that increases the risk of seizures (e.g., stroke, severe head trauma, significant metabolic disorders, etc.);
  • 15. By the judgment of the investigator, presence of any clinically significant hematologic, endocrine/metabolic, cardiovascular, respiratory, renal, hepatic, gastrointestinal, infectious, or neurological disease or the presence of an unstable or progressive chronic disease that unsuitable for entry into the study;
  • 16. History of , including solid tumors, hematologic malignancies, and carcinoma in situ (except completely resected and cured basal cell carcinoma of the skin, squamous cell carcinoma, and carcinoma in situ of the cervix), within 5 years prior to screening;
  • 17. Previous history of increased intraocular pressure or narrow-angle glaucoma;
  • 18. Subjects with conditions that interfere with the absorption of oral medications, such as active enteropathy, partial or complete intestinal obstruction, and chronic diarrhea, etc;
  • 19. Female subjects who are breastfeeding or have a positive pregnancy test during the screening period or during the study;
  • 20. Alcohol or drug dependence within 3 months before screening;
  • 21. Male or female with fertility do not agree to use an effective method of during the study and for 1 month after the end of the trial to ensure that contraception is effective for the sexual partner or for themselves;
  • 22. The subject meets any of the following conditions: unable to read or understand the study procedures or trial requirements; unwilling to comply with the trial restrictions or unable to return to the study site for assessments as scheduled; unable to personally provide (sign the informed consent form) prior to the trial.
  • 23. Subjects who in the opinion of the investigator, have any other condition that makes them unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
786 participants (actual)

Study arms

  • Experimental
    Ammoxetine group-cohort 1

    The eligible subjects will receive Ammoxetine plus placebo.

    Drug: Ammoxetine

  • Experimental
    Ammoxetine group-cohort 2

    The eligible subjects will receive Ammoxetine plus placebo.

    Drug: Ammoxetine

  • Placebo comparator
    Placebo group

    The eligible subjects will receive placebo.

    Drug: Placebo

  • Active comparator
    Sertraline group

    The eligible subjects will receive Sertraline plus placebo.

    Drug: Sertraline

Interventions

  • Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.

  • Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.

  • DrugPlacebo

    Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.

  • Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement

    Time frame: From baseline to Week 8

Secondary outcomes

  1. Change from baseline in Hamilton Depression Scale (HAMD-17) at the end of treatment (week 8)

    The HAMD-17 is a clinician-based assessment of depressive symptoms. The total score ranges from 0 to 53 with a higher score indicating more depression. A score of 0-9 is generally accepted to be within the normal range (or in clinical remission), while a score of greater than 17 indicates moderate to severe depression symptoms.

    Time frame: From baseline to Week 8

  2. Change from baseline in The Clinical Global Impression Scale (CGI-S) scores at the end of treatment (week 8) at the end of treatment (week 8)

    The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time.

    Time frame: From baseline to Week 8

  3. Clinical Global Impression Scale of Improvement (CGI-I) score at the end of treatment (week 8)

    The CGI-I scale is a clinician-rated instrument that measures the improvement of the participant's symptoms of depression. It is a 7-point scale where a score of 1 indicates that the participant is "very much improved," a score of 4 indicates that the participant has experienced "no change," and a score of 7 indicates that the participant is "very much worse."

    Time frame: Week 8

  4. The efficiency and remission of the MADRS score

    Effectiveness is defined as ≥ 50% reduction in MADRS score relative to baseline after treatment. Remission is defined as MADRS score ≤ 10 after treatment.

    Time frame: Baseline and week 8

  5. The efficiency and remission of the HAMD-17 score

    Effectiveness is defined as ≥50% reduction in HAMD-17 score relative to baseline after treatment. Remission is defined as HAMD-17 score ≤7 after treatment.

    Time frame: Baseline and week 8

  6. CGI-I score

    The CGI-I scale is a clinician-rated instrument that measures the improvement of the participant's symptoms of depression. It is a 7-point scale where a score of 1 indicates that the participant is "very much improved," a score of 4 indicates that the participant has experienced "no change," and a score of 7 indicates that the participant is "very much worse."

    Time frame: Week 1, week 2, week 4 and week 6

  7. Change from baseline in HAMD-17 score

    The HAMD-17 is a clinician-based assessment of depressive symptoms. The total score ranges from 0 to 53 with a higher score indicating more depression. A score of 0-9 is generally accepted to be within the normal range (or in clinical remission), while a score of greater than 17 indicates moderate to severe depression symptoms.

    Time frame: Week 1, week 2, week 4 and week 6

  8. Change from baseline in MADRS score

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

    Time frame: Week 1, week 2, week 4 and week 6

  9. Change from baseline in HAMA score

    The HAMA is a clinician-rated instrument administered to assess severity of anxiety, its improvement during the course of treatment, and the timing of such improvement. This instrument will be completed by qualified and trained Investigator site raters based on a semi-structured interview for his/her assessment of the participant. The scale consists of 14 items. Each item is rated on a scale of 0 (feeling not present) to 4 (very severe prevalence of the feeling). The HAMA total score is the sum of the 14 items and the score ranges from 0 to 56.

    Time frame: Week 1, week 2, week 4 and week 6

  10. Change from baseline in CGI-S score

    The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time.

    Time frame: Week 1, week 2, week 4 and week 6

  11. The efficiency and remission of the HAMD-17 score

    Effectiveness is defined as ≥50% reduction in HAMD-17 score relative to baseline after treatment. Remission is defined as HAMD-17 score ≤7 after treatment.

    Time frame: Week 1, week 2, week 4 and week 6

  12. The efficiency and remission of the MADRS score

    Effectiveness is defined as ≥ 50% reduction in MADRS score relative to baseline after treatment. Remission is defined as MADRS score ≤ 10 after treatment.

    Time frame: Week 1, week 2, week 4 and week 6

  13. The percentage of subjects with a MARDS score reduction ≥ 25%

    Time frame: Week 1and week 2

07

Study locations

2 sites
  • Peking University Sixth Hospital
    Beijing, Beijing Municipality 100000, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality 200000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2026, 16 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2026 → Jul 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Feb 14, 2025
StartActual
Feb 21, 2025
Primary completionActual
Jul 14, 2026was Jun 2026
CompletionActual
Aug 20, 2026was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 30, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Peking University Sixth Hospital · Beijing, China
  • Shanghai Mental Health Center · Shanghai, China
Oct 30, 2026
Start date
Feb 14, 2025→Feb 21, 2025 (actual)
Oct 30, 2026
Primary completion
Jun 30, 2026→Jul 14, 2026 (actual)
Oct 30, 2026
Study completion
Sep 30, 2026→Aug 20, 2026 (actual)
Oct 30, 2026
Enrollment
770 (estimated)→786 (actual)
Oct 30, 2026
Eligibility
3 exclusion criteria edited, 1 added
What changed in the criteria
Exclusion criteria
  • EditedSystemic Transcranial magnetic stimulation therapy (TMS)
  • EditedSystemic Vagus Nerve Stimulation (VNS)
  • EditedSystemic Light therapy, etc.
  • Added22. The subject meets any of the following conditions: unable to read or understand the study procedures or trial requirements; unwilling to comply with the trial restrictions or unable to return to the study site for assessments as scheduled; unable to personally provide informed consent (sign the informed consent form) prior to the trial.
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Completed
    2 sites added — first site in China
    Show 2 added (2 China)
    • Peking University Sixth Hospital · Beijing, China
    • Shanghai Mental Health Center · Shanghai, China
    Start date Feb 14, 2025→Feb 21, 2025 (now actual)
    Primary completion Jun 30, 2026→Jul 14, 2026 (now actual)
    Study completion Sep 30, 2026→Aug 20, 2026 (now actual)
    Enrollment 770 (estimated)→786 (actual)
    Eligibility 3 exclusion criteria edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • EditedSystemic Transcranial magnetic stimulation therapy (TMS)
    • EditedSystemic Vagus Nerve Stimulation (VNS)
    • EditedSystemic Light therapy, etc.
    • Added22. The subject meets any of the following conditions: unable to read or understand the study procedures or trial requirements; unwilling to comply with the trial restrictions or unable to return to the study site for assessments as scheduled; unable to personally provide informed consent (sign the informed consent form) prior to the trial.
    + 5 other changes: index terms, identifiers, verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06827431
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Feb 21, 2025
Primary completion
Jul 14, 2026
Completion
Aug 20, 2026
Last update
Oct 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ammoxetine

Start the discussion